<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05001854</url>
  </required_header>
  <id_info>
    <org_study_id>35RC19_8860</org_study_id>
    <secondary_id>2020-001430-35</secondary_id>
    <nct_id>NCT05001854</nct_id>
  </id_info>
  <brief_title>Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline Septic Shock Patients</brief_title>
  <acronym>FLUDROSEPSIS</acronym>
  <official_title>Evaluation of the Hemodynamics Effects of Fludrocortisone on the Pressor Response to Noradrenaline in Septic Shock Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H.A.C. PHARMA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefit of low-dose steroids in septic shock is still debated today, especially with&#xD;
      mineralocorticoids. Fludrocortisone is a synthetic mineralocorticoid, an analogue of&#xD;
      aldosterone, which has shown, in combination with hydrocortisone, a favorable effect on the&#xD;
      mortality of septic shock patients with relative adrenal insufficiency. In a previous study&#xD;
      in healthy volunteers, we showed for the first time that fludrocortisone at a dose of 400 μg&#xD;
      per day significantly improved the pressor response to phenylephrine. These results confirm&#xD;
      the observations reported in rats with endotoxin shock, where fludrocortisone was shown to&#xD;
      significantly increase blood pressure and contractile response to phenylephrine. These&#xD;
      encouraging results argue for a potential vascular beneficial effect of fludrocortisone and&#xD;
      need to be confirmed in a population of septic shock patients. In this context, we aimed to&#xD;
      evaluate the effect of oral administration of 100 μg every 6 hours of fludrocortisone on&#xD;
      vascular responsiveness to noradrenaline in septic shock patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients admitted to medical and surgical intensive care units with septic shock who meet the&#xD;
      selection criteria may be offered participation in the study. The consent is signed either by&#xD;
      the patient or his or her relative/legal representative if he or she is not capable or the&#xD;
      patient is included according to the emergency procedure in the absence of a relative. The&#xD;
      patient is managed according to the usual procedures for patients in septic shock. After&#xD;
      collection of the initial workup and basal measurements, the physician randomizes (=includes)&#xD;
      the patient into one of 2 arms : the patient receives either fludrocortisone (400 μg per&#xD;
      day), administered in 1 dose of 100 μg every 6 hours, i.e., 2 tablets of 50 μg per dose, or&#xD;
      the placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">April 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean arterial blood pressure (mmHg)</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Mean arterial blood pressure (mmHg) after a dose escalation of norepinephrine in increments of 0.2 μg/kg/min to a maximum dose of 1.5 μg/kg/min.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Baseline, before the first administration of the drug (fludrocortisone/placebo)</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>Heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial pressure</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>Mean arterial pressure, systolic arterial pressure, diasystolic arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial pressure</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Mean arterial pressure, systolic arterial pressure, diasystolic arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial pressure</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Mean arterial pressure, systolic arterial pressure, diasystolic arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>arterial pressure</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>Mean arterial pressure, systolic arterial pressure, diasystolic arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>Cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>Cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>Cardiac index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Cardiac index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Cardiac index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac index</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>Cardiac index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Systemic Vascular Resistances (ISVR)</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>Indexed Systemic Vascular Resistances (ISVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Systemic Vascular Resistances (ISVR)</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Indexed Systemic Vascular Resistances (ISVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Systemic Vascular Resistances (ISVR)</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Indexed Systemic Vascular Resistances (ISVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Systemic Vascular Resistances (ISVR)</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>Indexed Systemic Vascular Resistances (ISVR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Global Telediastolic Volume (IGVT)</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>Indexed Global Telediastolic Volume (IGVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Global Telediastolic Volume (IGVT)</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Indexed Global Telediastolic Volume (IGVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Global Telediastolic Volume (IGVT)</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Indexed Global Telediastolic Volume (IGVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Indexed Global Telediastolic Volume (IGVT)</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>Indexed Global Telediastolic Volume (IGVT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection Volume Variability (EVV)</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>Ejection Volume Variability (EVV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection Volume Variability (EVV)</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Ejection Volume Variability (EVV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection Volume Variability (EVV)</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Ejection Volume Variability (EVV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection Volume Variability (EVV)</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>v</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extravascular Pulmonary Water (EVW)</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>Extravascular Pulmonary Water (EVW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extravascular Pulmonary Water (EVW)</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>Extravascular Pulmonary Water (EVW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extravascular Pulmonary Water (EVW)</measure>
    <time_frame>After the 3rd administration of fludrocortisone or placebo (12 hours)</time_frame>
    <description>Extravascular Pulmonary Water (EVW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extravascular Pulmonary Water (EVW)</measure>
    <time_frame>After the 4th administration of fludrocortisone or placebo (18 hours)</time_frame>
    <description>Extravascular Pulmonary Water (EVW)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of deceased patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>Day 90</time_frame>
    <description>Percentage of deceased patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in intensive care unit</measure>
    <time_frame>Day 90</time_frame>
    <description>Length of stay in intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in care unit</measure>
    <time_frame>Day 90</time_frame>
    <description>Length of stay in care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to wean from catecholamines</measure>
    <time_frame>Day 90</time_frame>
    <description>Time to wean from catecholamines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation (MV)</measure>
    <time_frame>Day 90</time_frame>
    <description>Duration of mechanical ventilation (MV)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation markers</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>IFNγ, TNF α, IL1β, IL6, IL10 dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammation markers</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>IFNγ, TNF α, IL1β, IL6, IL10 dosage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>natremia dosage</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>blood sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>natremia dosage</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>blood sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary sodium dosage</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>urinary sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary sodium dosage</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>urinary sodium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kalemia dosage</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>blood potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kalemia dosage</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>blood potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary potassium dosage</measure>
    <time_frame>Baseline, before the first administration of the experimental drug (fludrocortisone/placebo)</time_frame>
    <description>urinary potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>urinary potassium dosage</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>urinary potassium</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pharmacokinetics of fludrocortisone : Area under the plasma concentration-time curve (plasma concentrations of fludrocortisone at 5 times)</measure>
    <time_frame>After 4th dose of fludrocortisone (18 hours)</time_frame>
    <description>in the experimental group only.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Dose-response relationship</measure>
    <time_frame>1,5 hours after the second administration of fludrocortisone or placebo (7,5 hours)</time_frame>
    <description>The dose-response relationship (mean arterial blood pressure to doses of norepinephrine) will be modeled according to a sigmoid Emax model with determination of the maximum effect (Emax) obtained on blood pressure, estimation of the dose of norepinephrine inducing half of the Emax (ED50), and the Hill coefficient γ reflecting the sigmoidality of the curve.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>Fludrocortisone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 μg every 6 hours of fludrocortisone per os&#xD;
A pharmacokinetic study is performed in this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 μg every 6 hours of placebo per os</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludrocortisone</intervention_name>
    <description>100 μg every 6 hours of fludrocortisone per os</description>
    <arm_group_label>Fludrocortisone</arm_group_label>
    <other_name>Flucortac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 μg every 6 hours of placebo per os</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Patient with septic shock for less than 24 hours, defined according to The Third&#xD;
             International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3) by the&#xD;
             combination of:&#xD;
&#xD;
               -  Sepsis defined as organ dysfunction caused by an inappropriate host response to&#xD;
                  infection (increase in SOFA score of at least 2 points secondary to infection),&#xD;
&#xD;
               -  Persistent hypotension requiring vasopressor drugs to maintain mean arterial&#xD;
                  pressure ≥ 65 mmHg,&#xD;
&#xD;
               -  Serum lactate level &gt; 2 mmol/l despite adequate vascular filling.&#xD;
&#xD;
          -  Hemodynamic stability for &gt;30 min with mean arterial pressure ≥ 65 mmHg and&#xD;
             noradrenaline dose ≤ 0.5 μg/kg/min,&#xD;
&#xD;
          -  Consent signed by the patient, family member, or legal representative or inclusion&#xD;
             under emergency procedure,&#xD;
&#xD;
          -  Negative to a diagnostic test for SARS-CoV2 less than 72 hours old; the test used must&#xD;
             be on the the list published on the Ministry of Solidarity and Health website&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          -  Current treatment with steroids or other treatment that may affect the&#xD;
             hypothalamic-pituitary-adrenal axis,&#xD;
&#xD;
          -  Anesthetic induction with etomidate within 6 hours prior to randomization given its&#xD;
             selective inhibitory effect on 11 β-hydroxylase,&#xD;
&#xD;
          -  Known hypersensitivity to fludrocortisone (or any of its excipients), or to&#xD;
             tetracosactide (Synacthen®),&#xD;
&#xD;
          -  Disturbed gastric emptying (gastric residue &gt; 500 ml) in the absence of an alternative&#xD;
             route of administration available (naso-jejunal tube or jejunostomy),&#xD;
&#xD;
          -  Pregnant or nursing woman,&#xD;
&#xD;
          -  Patient participating in another trial, possibly interfering with the study&#xD;
             procedures,&#xD;
&#xD;
          -  Person not affiliated to a social security system,&#xD;
&#xD;
          -  Known situation of deprivation of freedom (safeguard of justice), guardianship or&#xD;
             curatorship,&#xD;
&#xD;
          -  Patient with a life expectancy of less than 24 hours.&#xD;
&#xD;
          -  Patient with known or suspected SARS-CoV2 pneumonia&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients under court protection will be excluded as soon as the investigator is aware&#xD;
             of their status.&#xD;
&#xD;
          -  Hemodynamic worsening with noradrenaline dose &gt;1.5 μg/kg/min before evaluation of the&#xD;
             primary end point.&#xD;
&#xD;
          -  Catecholamine withdrawal before evaluation of the primary end point.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno Laviolle, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harmonie Perrichet, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rennes University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Harmonie Perrichet, MD</last_name>
    <phone>0033299284246</phone>
    <email>harmonie.perrichet@chu-rennes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie Veislinger, MSc</last_name>
    <phone>0033299283715</phone>
    <email>aurelie.veislinger@chu-rennes.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rennes University Hospital - Intensive Care unit</name>
      <address>
        <city>Rennes</city>
        <state>Bretagne</state>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Harmonie Perrichet, MD</last_name>
      <email>harmonie.perrichet@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Harmonie Perrichet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Septic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

